This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
The Promise of CGRP Antibodies to Change Practice in Migraine Treatment

The Promise of CGRP Antibodies to Change Practice in Migraine Treatment

Format

Monograph

Time to Complete

1.50 hours

Released

July 31, 2018

Expires

July 31, 2019
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 Credit(s)TM
1.50 / CNE for Nurses
1.50 / CE for Pharmacists (0.15 CEUs)

Accredited Provider



Provided by MediCom Worldwide, Inc.

Commercial Supporter

This activity is supported by an educational grant from Teva Pharmaceuticals.

Program Description

In this activity, the faculty will cover today’s clinical environment and the challenges associated with the effective preventive treatment of chronic migraines. Dr. Lipton, Dr. Charles, and Dr. Dodick will also highlight the challenges currently encountered by patients and clinicians when implementing current preventive treatment for migraine and share the promising new therapies on the horizon. This e-Monograph will include insights and understandings about how these new therapies work, the unique features of the calcitonin gene-related peptide (CGRP) monoclonal antibodies, how these four new agents have performed in clinical trials and, most importantly, how they may impact practice.

Intended Audience

This activity is designed for neurologists, primary care clinicians, nurses, and pharmacists specializing in headache management.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify the unmet needs resulting from ineffective prevention of migraine
  • Describe the role of CGRP in the pathophysiology of migraine
  • Compare and contrast emerging treatments currently in clinical trials which show promise to improve patient outcomes in the preventative treatment of episodic and chronic migraine

Conflict Of Interest Disclosure Policy

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty

David W. Dodick, MD – Chair
Professor of Neurology
Department of Neurology
Mayo Clinic
Phoenix, AR

Dr. Dodick has received honoraria as a consultant from Acorda, Alder BioPharmaceuticals Inc., Allergan, Inc., Amgen Inc., Autonomic Technologies, Inc., Boston Scientific Corporation, CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, eNeura Inc., GBS Ventures, Insys Therapeutics, Inc., Merck & Co., Inc., Promius Pharma, LLC., TEVA Pharmaceutical LTD, Tonix Pharmaceuticals Holding Corp., Trigemina, Inc., Xenon Pharmaceuticals Inc., and Zosano Pharma Corporation. He has received royalties from Cambridge University Press and Oxford University Press. He has stock options with EPIEN Medical, Inc., GBS/Nocira, and Mobile Health, and has a consulting use agreement with NAS.

Andrew C. Charles, MD
Professor of Neurology
UCLA School of Medicine
Los Angeles, CA

Dr. Charles has received honoraria as a consultant from Alder BioPharmaceuticals Inc., Amgen Inc., Biohaven Pharmaceuticals, Eli Lilly and Company, and eNeura Inc. He has received grant support related to research activities from Takeda Oncology.

Richard B. Lipton, MD
Professor of Neurology
Professor of Epidemiology and Population Health
Professor of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Bronx, NY

Dr. Lipton has served as a consultant, advisory board member, or has received honoraria from the American Academy of Neurology, Alder BioPharmaceuticals Inc., Allergan, Inc., American Headache Society, Amgen Inc., Autonomic Technologies, Inc., Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, BioVision Inc., Boston Scientific Corporation, CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura Inc., GlaxoSmithKline plc, Merck & Co., Inc., PERNIX Therapeutics, Pfizer Inc., Supernus Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Trigemina, Inc., Vector Pharma, and Vedanta Biosciences, Inc. He has received grant support related to research activities from the National Institutes of Health (NIH), Migraine Research Foundation, and the National Headache Foundation. He has also received royalties from Wolff’s Headache, Oxford University Press, Wiley, and Informa. He owns stock options in eNeura Therapeutics and Biohaven Holdings.

Planning Committee Disclosure

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity:
Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.50

Type

CNE Contact Hour(s)

Accreditation Statement

MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380.

Designation Statement

MediCom designates this CNE activity for 1.50 contact hours. Program Number: 18-003-072

Credit

1.50

Type

CE for Pharmacists

Accreditation Statement

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.50 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-003-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue